- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01680471
A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery
Comparative Study on the Effects of Capacities of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery : a Randomized Double- Blinded Trial
Sevoflurane with its rapid induction and emergence, hemodynamic stability, and nonirritating airway properties, has acquired widespread acceptance in children. However, sevoflurane has been reported to be associated with emergence agitation in children, with a reported incidence of up to 80%.
The purpose of this study is to verify that the prophylactic use of midazolam, which is a GABA A receptor inhibitor, given five minutes before the end of strabismus surgery reduces the incidence of emergence agitation after sevoflurane anesthesia in children. Simultaneously, this study aims to find out the proper dose of midazolam with minimum disturbance to patient's emergence time.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Seoul, Korea, Republikken, 136-705
- Department of Anaesthesiology and Pain Medicine Department; Korea University Anam Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- American Society of Anesthesiologists physical status I and II patients
- Aged one to 13 years scheduled to undergo strabismus surgery under general anesthesia
- Willing to be assigned to any of the study intervention groups
Exclusion Criteria:
- Refusal by parents
- Neurological disease
- Developmental delay
- History of any previous surgery
- Airway disease
- American Society of Anesthesiologists physical status score of III or IV
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Midazolam 0.03mg/kg
This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
|
This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery. If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Andre navne:
|
|
Eksperimentel: Midazolam 0.05mg/kg
This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
|
This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery. If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Andre navne:
|
|
Placebo komparator: Placebo
This group will be injected intravenous normal saline five minutes before the end of surgery.
|
This group will be injected intravenous normal saline five minutes before the end of surgery. If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time of emergence
Tidsramme: within the first 1hour after end of surgery
|
The time of emergence is defined as time interval from the time of discontinuation of sevoflurane to the time of extubation.
|
within the first 1hour after end of surgery
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of emergency agitation
Tidsramme: From just after extubation until the discharge of PACU, assessed up to 1 hour
|
Agitation is assessed immediately after extubation, and continuously thereafter until participants are calm.
Emergence agitation is evaluated using the four-point emergence scale and the pediatric anesthesia emergence delirium scale.
The highest scores are recorded.
|
From just after extubation until the discharge of PACU, assessed up to 1 hour
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Eun Jung Cho, Resident, Department of Anaesthesiology and Pain Medicine Department, Korea University Anam Hospital
- Studieleder: S.Z. Yoon, Professor, Department of Anaesthesiology and Pain Medicine Department, Korea University Anam Hospital
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Psykiske lidelser
- Patologiske processer
- Sygdomme i nervesystemet
- Øjensygdomme
- Postoperative komplikationer
- Neurologiske manifestationer
- Forvirring
- Neuroadfærdsmæssige manifestationer
- Neurokognitive lidelser
- Sygdomme i kranienerve
- Øjenmotilitetsforstyrrelser
- Delirium
- Strabismus
- Emergence Delirium
- Lægemidlers fysiologiske virkninger
- Neurotransmittermidler
- Molekylære mekanismer for farmakologisk virkning
- Depressive midler til centralnervesystemet
- Bedøvelsesmidler, intravenøst
- Bedøvelsesmidler, general
- Bedøvelsesmidler
- Beroligende midler
- Psykotropiske stoffer
- Hypnotika og beroligende midler
- Adjuvanser, anæstesi
- Anti-angst midler
- GABA modulatorer
- GABA agenter
- Midazolam
Andre undersøgelses-id-numre
- ECho2012
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Barn
-
MedDay Pharmaceuticals SAEurofins OptimedAfsluttetSunde frivillige | Nedsat leverfunktion af moderat Child Pugh-kategoriFrankrig, Ungarn
-
RenJi HospitalAfsluttetBlodpladeantal/miltdiameterforhold | Child-Pugh klassificeringKina
-
Stanford UniversityNational Cancer Institute (NCI)AfsluttetTilbagevendende hepatocellulært karcinom | Child-Pugh klasse A | Child-Pugh klasse BForenede Stater, Japan
-
Ohio State University Comprehensive Cancer CenterVarian Medical SystemsAfsluttetChild-Pugh klasse A | Stadium IIIA Hepatocellulært karcinom | Stadium IIIB hepatocellulært karcinom | Stadium IIIC hepatocellulært karcinom | Stadium IVA Hepatocellulært karcinom | Stadium IVB Hepatocellulært karcinom | Child-Pugh klasse BForenede Stater
-
Centre Hospitalier Universitaire DijonAfsluttetChild-Pugh A Hepatocellulært karcinomFrankrig
-
MindRank AI LtdIkke rekrutterer endnuHepatic Impairment (Mild and Moderate, Child-Pugh Class A and B) | Leverinsufficiens (MeSH ID: D048550)Kina
-
CatalYm GmbHRekrutteringChild-Pugh A Hepatocellulært karcinom | Ikke-operabelt eller metastatisk hepatocellulært karcinom | Svigt af førstelinjebehandling, der omfattede et godkendt anti-PD-(L)1-kompoundItalien, Tyskland
-
Roswell Park Cancer InstituteMerck Sharp & Dohme LLCAfsluttetAvanceret hepatocellulært karcinom hos voksne | Child-Pugh klasse A | Trin III hepatocellulært karcinom | Stadium IIIA Hepatocellulært karcinom | Stadium IIIB hepatocellulært karcinom | Stadium IIIC hepatocellulært karcinom | Trin IV hepatocellulært karcinom | Stadium IVA Hepatocellulært karcinom | Stadium...Forenede Stater
-
AstraZenecaAfsluttetMavekræft | Avancerede solide maligniteter | Solid tumor | Child-Pugh A til B7 avanceret hepatocellulært karcinom | EGFR og/eller ROS Mutant NSCLC | LungemetastasekarcinomKorea, Republikken
Kliniske forsøg med Midazolam 0.03mg/kg
-
Zhuji People's Hospital of Zhejiang ProvinceAfsluttetKejsersnit | Effektivitet | Sikkerhed | Præeklampsi | MidazolamKina
-
Yonsei UniversityAfsluttetTidlig mavekræft | Gastrisk adenomKorea, Republikken
-
Nationwide Children's HospitalTrukket tilbageSikkerhed og effekt af intranasal dexmedetomidin, fentanyl og midazolam på den pædiatriske skadestueSmerte | Angst | Akut stresslidelseForenede Stater
-
Atridia Pty Ltd.Linear Clinical ResearchAfsluttet
-
Genor Biopharma Co., Ltd.Ukendt
-
Cairo UniversityIkke rekrutterer endnuPræoperativ angst | Preoperativ angst oplevet af den pædiatriske patientEgypten
-
Hangzhou Grand Biologic Pharmaceutical, Inc.Peking Union Medical College HospitalAfsluttet
-
Green Cross CorporationAfsluttetMucopolysaccharidosis IIKorea, Republikken
-
Diskapi Yildirim Beyazit Education and Research...Ikke rekrutterer endnuPædiatrisk anæstesi | PræmedicineringTyrkiet (Türkiye)
-
Seoul National University HospitalAfsluttetPlasma volumen | TidevandsvolumenKorea, Republikken